Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice (IRIS Skypoint)
a Non-randomized, Prospective, Open-label Registry to Compare the Effectiveness and Safety of XIENCE Skypoint™ Stents Versus Other DESs in Patients With Coronary Artery Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Jung-Hee Ham, Project manager
- Phone Number: 82230104728
- Email: cvcrc5@amc.seoul.kr
Study Locations
-
-
-
Seoul, South Korea
- Recruiting
- Asan Medical Hospital
-
Contact:
- Seung-Jung Park, MD
- Email: sjpark@amc.seoul.kr
-
Principal Investigator:
- Seung-jung Park, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients ≥ 19 years old
- Patients receiving Xience-Skypoint™ stents.
- The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.
Exclusion Criteria:
- Patients with a mixture of other DESs
- Terminal illness with life expectancy <1 year
- Patients with cardiogenic shock
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
XIENCE Skypoint™ stent
Patients receiving Xience-Skypoint™ stents
|
Percutaneous coronary intervention with Xience-Skypoint™ stent
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the composite event rate of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR)
Time Frame: 12 months
|
the composite of death, nonfatal myocardial infarction (MI), or ischemic-driven Target- Vessel Revascularization (TVR) at 12 months post procedure. A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event is considered to have occurred if any one of several different events is observed. |
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the event rate of all cause death
Time Frame: 5 years
|
5 years
|
|
|
the event rate of cardiac death
Time Frame: 5 years
|
5 years
|
|
|
the event rate of nonfatal myocardial infarction
Time Frame: 5 years
|
5 years
|
|
|
the composite event rate of death, or nonfatal myocardial infarction (MI)
Time Frame: 5 years
|
5 years
|
|
|
the composite event rate of cardiac death, or nonfatal myocardial infarction (MI)
Time Frame: 5 years
|
5 years
|
|
|
the event rate of Target- Vessel Revascularization (TVR)
Time Frame: 5 years
|
5 years
|
|
|
the event rate of Target- lesion Revascularization (TLR)
Time Frame: 5 years
|
5 years
|
|
|
the event rate of stent thrombosis
Time Frame: 5 years
|
according to an Academic Research Consortium (ARC) criteria
|
5 years
|
|
the event rate of stroke
Time Frame: 5 years
|
5 years
|
|
|
the event rate of Procedural success
Time Frame: 7 days
|
(defined as achievement of a final diameter stenosis of <30% by visual estimation, without the occurrence of death, Q-wave MI, or urgent revascularization during the index hospitalization.
|
7 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AMCCV2023-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.